SUDA Pharmaceuticals Limited announced the following changes to its senior management team. The US based business development role, headed by Andrew Curtis, will cease in 30 days time. This function will be assumed by the incoming CEO and the Company's international business development will be serviced from Australia.

Other cost savings include Mr. Joseph Ohayon, SUDA's Company Secretary and Chief Financial Officer, will move from full time to part time working three days per week and an operational support role will be terminated.